Cargando…

Antidepressant Use and Lung Cancer Risk and Survival: A Meta-analysis of Observational Studies

Recent preclinical studies have linked antidepressants (AD) to their potential anticancer effects in multiple cancers, but the impact on lung cancer remains unclear. This meta-analysis examined the associations between ADs and lung cancer incidence and survival. The Web of Science, Medline, CINAHL,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Eunkyung, Park, Yongho, Li, David, Rodriguez-Fuguet, Alice, Wang, Xiaochuan, Zhang, Wen Cai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259481/
https://www.ncbi.nlm.nih.gov/pubmed/37377607
http://dx.doi.org/10.1158/2767-9764.CRC-23-0003
_version_ 1785057669489360896
author Lee, Eunkyung
Park, Yongho
Li, David
Rodriguez-Fuguet, Alice
Wang, Xiaochuan
Zhang, Wen Cai
author_facet Lee, Eunkyung
Park, Yongho
Li, David
Rodriguez-Fuguet, Alice
Wang, Xiaochuan
Zhang, Wen Cai
author_sort Lee, Eunkyung
collection PubMed
description Recent preclinical studies have linked antidepressants (AD) to their potential anticancer effects in multiple cancers, but the impact on lung cancer remains unclear. This meta-analysis examined the associations between ADs and lung cancer incidence and survival. The Web of Science, Medline, CINAHL, and PsycINFO databases were searched to identify eligible studies published by June 2022. We conducted a meta-analysis using a random-effects model to compare the pooled risk ratio (RR) and 95% confidence interval (CI) in those treated with or without ADs. Heterogeneity was examined using Cochran Q test and inconsistency I(2) statistics. The methodologic quality of the selected studies was assessed using the Newcastle-Ottawa Scale for observational studies. Our analysis, including 11 publications involving 1,200,885 participants, showed that AD use increased lung cancer risk by 11% (RR = 1.11; 95% CI = 1.02–1.20; I(2) = 65.03%; n = 6) but was not associated with overall survival (RR = 1.04; 95% CI = 0.75–1.45; I(2) = 83.40%; n = 4). One study examined cancer-specific survival. Subgroup analysis showed that serotonin and norepinephrine reuptake inhibitors (SNRIs) were associated with an increased lung cancer risk by 38% (RR = 1.38; 95% CI = 1.07–1.78; n = 2). The quality of selected studies was good (n = 5) to fair (n = 6). Our data analysis suggests that SNRIs were associated with an elevated risk of lung cancer, raising concerns regarding the use of AD treatment in patients vulnerable to lung cancer. The effects of ADs—particularly SNRIs—and their interplay with cigarette use and lung cancer risk in vulnerable patients merits further study. SIGNIFICANCE: In this meta-analysis of 11 observational studies, we found evidence of a statistically significant association between the use of certain ADs and lung cancer risk. This effect merits further study, particularly as it relates to known environmental and behavioral drivers of lung cancer risk, such as air pollution and cigarette smoke.
format Online
Article
Text
id pubmed-10259481
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-102594812023-06-13 Antidepressant Use and Lung Cancer Risk and Survival: A Meta-analysis of Observational Studies Lee, Eunkyung Park, Yongho Li, David Rodriguez-Fuguet, Alice Wang, Xiaochuan Zhang, Wen Cai Cancer Res Commun Research Article Recent preclinical studies have linked antidepressants (AD) to their potential anticancer effects in multiple cancers, but the impact on lung cancer remains unclear. This meta-analysis examined the associations between ADs and lung cancer incidence and survival. The Web of Science, Medline, CINAHL, and PsycINFO databases were searched to identify eligible studies published by June 2022. We conducted a meta-analysis using a random-effects model to compare the pooled risk ratio (RR) and 95% confidence interval (CI) in those treated with or without ADs. Heterogeneity was examined using Cochran Q test and inconsistency I(2) statistics. The methodologic quality of the selected studies was assessed using the Newcastle-Ottawa Scale for observational studies. Our analysis, including 11 publications involving 1,200,885 participants, showed that AD use increased lung cancer risk by 11% (RR = 1.11; 95% CI = 1.02–1.20; I(2) = 65.03%; n = 6) but was not associated with overall survival (RR = 1.04; 95% CI = 0.75–1.45; I(2) = 83.40%; n = 4). One study examined cancer-specific survival. Subgroup analysis showed that serotonin and norepinephrine reuptake inhibitors (SNRIs) were associated with an increased lung cancer risk by 38% (RR = 1.38; 95% CI = 1.07–1.78; n = 2). The quality of selected studies was good (n = 5) to fair (n = 6). Our data analysis suggests that SNRIs were associated with an elevated risk of lung cancer, raising concerns regarding the use of AD treatment in patients vulnerable to lung cancer. The effects of ADs—particularly SNRIs—and their interplay with cigarette use and lung cancer risk in vulnerable patients merits further study. SIGNIFICANCE: In this meta-analysis of 11 observational studies, we found evidence of a statistically significant association between the use of certain ADs and lung cancer risk. This effect merits further study, particularly as it relates to known environmental and behavioral drivers of lung cancer risk, such as air pollution and cigarette smoke. American Association for Cancer Research 2023-06-12 /pmc/articles/PMC10259481/ /pubmed/37377607 http://dx.doi.org/10.1158/2767-9764.CRC-23-0003 Text en © 2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by/4.0/This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.
spellingShingle Research Article
Lee, Eunkyung
Park, Yongho
Li, David
Rodriguez-Fuguet, Alice
Wang, Xiaochuan
Zhang, Wen Cai
Antidepressant Use and Lung Cancer Risk and Survival: A Meta-analysis of Observational Studies
title Antidepressant Use and Lung Cancer Risk and Survival: A Meta-analysis of Observational Studies
title_full Antidepressant Use and Lung Cancer Risk and Survival: A Meta-analysis of Observational Studies
title_fullStr Antidepressant Use and Lung Cancer Risk and Survival: A Meta-analysis of Observational Studies
title_full_unstemmed Antidepressant Use and Lung Cancer Risk and Survival: A Meta-analysis of Observational Studies
title_short Antidepressant Use and Lung Cancer Risk and Survival: A Meta-analysis of Observational Studies
title_sort antidepressant use and lung cancer risk and survival: a meta-analysis of observational studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259481/
https://www.ncbi.nlm.nih.gov/pubmed/37377607
http://dx.doi.org/10.1158/2767-9764.CRC-23-0003
work_keys_str_mv AT leeeunkyung antidepressantuseandlungcancerriskandsurvivalametaanalysisofobservationalstudies
AT parkyongho antidepressantuseandlungcancerriskandsurvivalametaanalysisofobservationalstudies
AT lidavid antidepressantuseandlungcancerriskandsurvivalametaanalysisofobservationalstudies
AT rodriguezfuguetalice antidepressantuseandlungcancerriskandsurvivalametaanalysisofobservationalstudies
AT wangxiaochuan antidepressantuseandlungcancerriskandsurvivalametaanalysisofobservationalstudies
AT zhangwencai antidepressantuseandlungcancerriskandsurvivalametaanalysisofobservationalstudies